A case of arrhythmogenic right ventricular cardiomyopathy presenting with progressive right ventricular failure and recurrent multifocal monomorphic ventricular tachycardia during 15 years of follow-up  by Kuwabara, Kensuke et al.
Journal of Cardiology Cases 10 (2014) 216–220Case Report
A case of arrhythmogenic right ventricular cardiomyopathy presenting
with progressive right ventricular failure and recurrent multifocal
monomorphic ventricular tachycardia during 15 years of follow-up
Kensuke Kuwabara (MD)*, Kazuhito Hirata (MD), Minoru Wake (MD),
Takanori Takahashi (MD), Jun Nakazato (MD), Nobuhito Yagi (MD), Asako Fukuyama (MD)
The Division of Cardiology, Okinawa Chubu Hospital, Okinawa, Japan
A R T I C L E I N F O
Article history:
Received 6 March 2014
Received in revised form 29 July 2014
Accepted 31 July 2014
Keywords:
Arrhythmogenic right ventricular
cardiomyopathy
Right ventricular failure
Ventricular tachycardia
A B S T R A C T
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a multigenic form of cardiomyopathy
characterized by myocardial loss and ﬁbrofatty replacement mainly in the right ventricle. Progressive
right ventricular dysfunction, ventricular arrhythmias, and sudden cardiac death are the clinical picture
of this disease. Despite its clinical importance as a cause of sudden death, ARVC is likely to be under-
recognized. In case reports about ARVC, disease characteristics such as arrhythmias, images, and genes
are described in fragments. Little is reported about the long-term course of ARVC in the same patient. In
this report, we present a case of a 68-year-old male who was diagnosed with ARVC after his ﬁrst episode
of ventricular tachycardia. Both mechanical and electrical progression were seen during the 15 years of
follow-up, requiring the modiﬁcation of disease management. This report could help improve the
understanding of this rare disease, and the way of its management.
<Learning objective: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a multigenic form of
cardiomyopathy characterized by ﬁbrofatty degeneration mostly in right ventricular myocardium.
Despite its importance as a cause of sudden death, ARVC is likely to be under-recognized. This paper
describes the progressive course of ARVC conﬁrmed both clinically and pathologically during 15 years of
follow-up, which could help improve understanding of this disease.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
characterized by ﬁbrofatty degeneration mainly in the right
ventricular myocardium [1]. The prevalence of ARVC is reported
to be 0.02–0.1% [2,3]. Progressive right ventricular dysfunction,
ventricular arrhythmias, and sudden cardiac death are the clinical
features. Little has been reported on the long-term course of this
rare disease. This paper describes the progressive course of ARVC
conﬁrmed both clinically and pathologically during 15 years of
follow-up.* Corresponding author at: The Division of Cardiology, Sendai Kousei Hospital, 4-15
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A 68-year-old male was admitted to our hospital (Fig. 1)
because of monomorphic ventricular tachycardia (VT).
His initial presentation dates back 15 years, when he ﬁrst
developed sustained monomorphic VT requiring cardioversion
(Figs. 1 and 2A). At that time he was hospitalized and evaluated
(Fig. 1). There was no family history of speciﬁc cardiovascular
disease. On physical examination, jugular venous pressure was not
elevated, and there was no leg edema. No cardiac murmur was
heard on auscultation. Chest radiograph showed normal cardio-
thoracic ratio (CTR) of 49% and no signs of lung congestion.
Electrocardiogram (ECG) obtained during normal sinus rhythm
showed e-waves on leads V1 and V2 (Fig. 3A). Echocardiography
revealed dilated right ventricle (RV), while left ventricular (LV) size
and systolic function were maintained (Fig. 3C). Cardiac catheteri-
zation showed normal pressure in each cardiac chamber (Fig. 4A),
and coronary angiography was normal. Endomyocardial biopsy
showed mild ﬁbrosis and disarray of myocardial ﬁbers (Fig. 4B).s reserved.
Fig. 1.
Clinical course during the 15 years of follow-up. Initially, the patient presented with a ventricular tachycardia (VT) but did not have the signs and symptoms of
mechanical heart failure except for right ventricular dilatation. As the disease progressed, the signs and symptoms of right heart failure gradually became overt as
manifested by leg edema, ascites, elevated jugular venous pulse (JVP) and increased cardiothoracic ratio (CTR). *1 represents the initial presentation and *2
represents the current presentation. y1–5 represent episodes of VT. EMB, endomyocardial biopsy; ECG, electrocardiogram; Echo, echocardiogram.
Fig. 2.
Ventricular tachycardia (VT) morphology. (A) The ﬁrst VT recorded at the time of diagnosis. (B–E) Four different forms of VT occurred during the 15 years of
follow-up. (A–E) Respectively represent y1–5 in Fig. 1. (D) and (E) show VT morphology of the inferior axis.
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Fig. 3.
Electrocardiographic and echocardiographic ﬁndings at the initial (A, C) and the current presentation (B, D). (A) The initial electrocardiogram (ECG) obtained after
cardioversion (*1 in Fig. 1), showing normal sinus rhythm with right bundle branch block pattern. An e-wave is indicated by the black arrow. (B) ECG obtained
15 years after the diagnosis (*2 in Fig. 1). The loss of QRS voltages in precordial leads and the prolongation of the QRS duration show the progression of
arrhythmogenic right ventricular cardiomyopathy (ARVC). (C) The initial echocardiography, showing dilated right ventricle (RV) with preserved left ventricular
(LV) function [LV ejection fraction (EF) 50%, *1 in Fig. 1]. (D) The echocardiography obtained 15 years after the diagnosis (*2 in Fig. 1). RV is further dilated and LV
function is signiﬁcantly reduced (LVEF 33%), representing biventricular involvement pattern in the course of ARVC.
Fig. 4.
The comparison of the pressure tracings at cardiac catheterization and the biopsy ﬁndings between the initial and the current presentation (A and B represent *1,
C and D represent *2 in Fig. 1, respectively). (A) The right atrial mean pressure was 6–7 mmHg and the ‘‘a’’ wave was dominant. Mean pulmonary arterial wedge
pressure was 12 mmHg. There was no pulmonary hypertension (25/11 mmHg, mean pressure 17 mmHg). (B) Hematoxylin–eosin staining of endomyocardium
obtained from RV apex at the time of diagnosis. Three samples were obtained from RV apex, showing generally the same extent of ﬁbrosis and myocardial loss.
One of those samples is presented as a representative image here. Mild ﬁbrosis and disarray of myocardial ﬁbers are seen. Fibrofatty degeneration is not
remarkable. (C) The right atrial pressure was elevated to 13 mmHg and a ‘‘v’’ wave became prominent, resulting in the ‘‘ventricularization’’ of the shape. This is
also visually appreciated with the inspection of the jugular vein (Video 1). There was no pulmonary hypertension (30/13 mmHg, mean pressure 20 mmHg).
(D) Repeated biopsy from the RV apex 15 years after the diagnosis. Three samples were obtained from RV apex again, showing marked loss of myocytes with
ﬁbrofatty degeneration. AO, aorta, LV, left ventricle; WP, pulmonary arterial wedge pressure; PA, pulmonary artery; RA, right atrium; RV, right ventricle.
K. Kuwabara et al. / Journal of Cardiology Cases 10 (2014) 216–220218
K. Kuwabara et al. / Journal of Cardiology Cases 10 (2014) 216–220 219Based on those ﬁndings, he was diagnosed as having ARVC. He
underwent catheter ablation for VT. He had been asymptomatic for
3 years after the diagnosis, but he developed two episodes of
sustained monomorphic VT with different morphologic character-
istics (Figs. 1 and 2B and C). At that time, he was treated with oral
amiodarone 200 mg daily. There were no further episodes of VT for
the following 12 years.
His non-cardiac medical history was remarkable for hyperten-
sion, diabetes mellitus, chronic kidney disease, and bronchial
asthma. He had also developed splenic infarction 11 years after the
diagnosis, although atrial ﬁbrillation was not detected at that time.
Anticoagulation therapy was started.
In the year prior to this admission (14 years after the diagnosis),
he gradually developed leg edema, ascites, and dyspnea on
exertion. He also developed atrial ﬂutter, which was converted
to sinus rhythm with cardioversion. Despite the adjustment of
medical therapy, right heart failure progressed, and ﬁnally
he developed palpitations and chest discomfort and was taken
to our hospital (Fig. 1). On admission, initial blood pressure was
104/60 mmHg and heart rate was 140 bpm, and ECG revealed
sustained monomorphic VT (Figs. 1 and 2D). Cardioversion was
required to restore normal sinus rhythm. He also developed
another episode of VT with different morphology during this
hospitalization (Figs. 1 and 2E). He was admitted for the treatment
of progressive right heart failure and VT. On physical examination,
jugular vein was distended (Video 1) and bilateral leg edema was
seen. Grade 2 systolic murmur was heard at the left lower sternal
border. Aortic and pulmonary components of the second heart
sound were widely split. Chest radiograph showed cardiomegaly
without pulmonary edema (CTR was 65%). ECG revealed the loss of
QRS voltages and the prolongation of QRS interval compared with
the previous ECGs (Fig. 3B). In addition to marked dilatation of RV,
reduced LV ejection fraction (33%) and abnormal septal movement
were seen on echocardiography (Fig. 3D, Video 2). Cardiac
catheterization showed elevated right atrial pressure without
signiﬁcant pulmonary artery hypertension (Fig. 4C). Right ven-
triculography showed markedly enlarged RV with mild tricuspid
regurgitation, and RV was diffusely hypokinetic (Video 3).
Endomyocardial biopsy from the RV apex showed marked loss
of myocytes with ﬁbrofatty degeneration (Fig. 4D). On electrophys-
iological study, two sustained monomorphic VTs with different
morphologic characteristics were easily and reproducibly induced
by programmed ventricular stimulation with double extra-stimuli,
and were terminated with anti-tachycardia pacing. One of the VTs
had the same morphology as Fig. 2E, and the other was different
from any VTs recorded before. The dosage of amiodarone was
increased to 300 mg daily and an implantable cardioverter
deﬁbrillator (ICD) was implanted.
With the use of furosemide and carperitide infusion therapy, he
was discharged without complications. However, during the
outpatient follow-up, the ICD memory showed several episodes
of VT, which were successfully treated with anti-tachycardia
pacing. In addition, high-dose diuretics and repeat abdominal
paracentesis were required for the symptom control of advanced
right heart failure.
Discussion
ARVC predominantly affects RV myocardium. Pathologically, it
causes ﬁbrofatty degeneration, clinically resulting in RV dilatation,
RV failure, ventricular arrhythmias and sudden cardiac death. Four
clinical stages are reported in the course of ARVC [4]: (1) concealed
phase (no clinical manifestations of ARVC, but potential risk of
sudden cardiac death); (2) overt electrical disorder phase
(characterized by symptomatic arrhythmias); (3) RV failure phase;
and (4) biventricular pump failure phase. In reports about ARVC,disease characteristics such as arrhythmias, images, and genes are
described in fragments. Little has been reported about the long-
term course of ARVC. In our case, we could follow the disease
progression from the beginning of overt electrical disorder phase
to biventricular pump failure phase in detail in a single patient in
the same institution.
The most important ﬁnding in this case is that the electrical
progression is associated with the mechanical progression in the
course of ARVC. Progressive right heart failure represented by the
deterioration of leg edema, jugular vein distension, and ascites was
detected late in the follow-up. Serial chest radiographs showed
progressive enlargement of the CTR, and ECG showed the
progressive loss of QRS voltage and the prolongation of QRS
duration. Pressure tracings in the follow-up catheterization
revealed markedly elevated RA pressure with equally prominent
‘‘a’’ and ‘‘v’’ wave, compared with the initial pressure tracings.
Beside the progressive worsening of RV dilatation, LV also became
involved. All of these clinical ﬁndings appeared to be correlated
with the pathological ﬁndings in the serial biopsy showing the
progression of ﬁbrofatty degeneration and loss of myocardium.
Regarding the arrhythmic events, there were three clusters of
VT episodes during the follow-up of 15 years. As shown in Fig. 1,
the ﬁrst cluster was seen in the initial presentation (at the
beginning of overt electrical disorder phase), when the electrical
and histopathological abnormalities had already been present but
no clinical signs and symptoms of heart failure were seen. The
patient remained uneventful after the successful radiofrequency
ablation, but VTs with different morphology occurred three years
later. This was successfully managed with the administration of
amiodarone. The third cluster was seen 15 years after the initial
presentation, one year after he started to have the signs of heart
failure. The mechanism of the arrhythmia in ARVC is mainly
explained by the scar-related macro-reentrant ventricular tachy-
cardia. It is assumed that during the disease progression as
reﬂected by the serial changes in echocardiography, cardiac
catheterization, and biopsy, multiple new reentry substrates were
created and that made the arrhythmia more difﬁcult to control.
Also, the VT morphology in the current presentation (Fig. 2D and E)
had inferior axis, different from those in overt electrical disorder
phase (Fig. 2A–C), showing the widespread substrates due to the
disease progression.
From the clinical aspect, sudden cardiac death (SCD) is the most
severe manifestation of ARVC and occurs at any phase. ICD is
indicated for the secondary prevention of SCD in patients with
sustained VT or ventricular ﬁbrillation [5]. But the suitable group
for primary prevention is still unclear. Currently, possible clinical
predictors of SCD include the history of previous cardiac arrest,
syncope, documented VT, severe RV/LV dysfunction, younger age,
and the extent of T wave inversion across the 12-lead ECG [6,7]. We
decided to implant ICD in this patient because he was considered
to be at high risk for SCD. Catheter ablation of VT in ARVC patients
has a limited effect due to the multiple reentry substrates and
epicardial involvements, which are represented by the multiple
VTs seen and induced in our case. Because of the high rate of
recurrence, and the fact that VT was easily terminated with anti-
tachycardia pacing, catheter ablation was deferred this time, but
will be necessary in the future if the VT becomes more frequent and
refractory.
The patient with ARVC should be serially followed for both
electrical and mechanical progression by careful history taking,
physical examination, ECG, and echocardiography, although the
ideal modality and interval are not known. A recent study shows
possible superiority of cardiac magnetic resonance imaging to
echocardiography [8], which was not performed in this case. The
occurrence of heart failure is important as a major prognostic
factor, and therefore should be checked in daily practice.
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jccase.2014.07.014.
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